Abstract:Mpox (formerly known as monkeypox), which has symptoms similar to smallpox, is a zoonotic disease caused by the monkeypox virus (MPXV). From 1 January 2022 to 31 March 2024, 117 countries, territories, or areas reported 95,226 laboratory-confirmed cases of Mpox (including 185 deaths) to the World Health Organization. However, as there is no licensed specific MPXV vaccine available globally, the vaccines currently used for mpox prevention are mostly smallpox vaccines. Thus, the rapid development of safe and effective vaccines is urgently required. In the present study, the key MPXV proteins A35, B6R, E8L, A29, M1R, and H3L were expressed and prepared using a prokaryotic expression system (Escherichia coli) and a eukaryotic expression system (yeast), and the fusion antigens A35-A29 and A35-M1R were constructed based on the dimerization characteristics of the A35 protein. By combining the antigens with aluminum hydroxide and CpG adjuvants in different combinations, we developed nine multicomponent MPXV subunit vaccine candidates. Each antigen (10 μg) and fusion antigen (20 μg) were used to immunize the mice. The first two doses produced a mean titer of 10(Petersen et al., 2016 [5]), and the third dose maintained the same potent antibody-specific response as the previous two immunizations. The protective activity of different antigen combinations was determined using the cell neutralization test of vaccinia virus (VACV), which showed that the subunit vaccine candidates with two to six components (MPXV6/5/4/3a/3b/Fa/2a) had good neutralizing activity, and antigens A35 and M1R could produce neutralizing antibodies against VACV. The neutralizing antibody titer of the fusion antigen MPXVFa (A35-M1R), detected 2 weeks after the second booster dose, was comparable with that of MPXV2a (A35 and M1R). The A35-M1R fusion protein not only provided a high level of protection as a protective antigen but also simplified the preparation of candidate antigens. In summary, we systematically investigated the different protective antigen candidates of MPXV that have been widely studied and provided critical insights into the key protective antigen composition for vaccines, thus establishing a technical and theoretical foundation for the development of MPXV subunit vaccines.

Different immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses

Old and new mpox vaccine

Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques

Reactogenicity and immunogenicity against MPXV of the intradermal administration of Modified V Vaccinia Ankara compared to the standard subcutaneous route.

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity

Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus

Rational development of multicomponent mRNA vaccine candidates against mpox

Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections

mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization

Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease

Mpox mRNA-1769 Vaccine Inhibits Orthopoxvirus Replication at Intranasal, Intrarectal, and Cutaneous Sites of Inoculation

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

Evaluation of a multiplexed immunoassay for assessing long-term humoral immunity Orthopoxviruses

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

Vaccines against mpox: MVA-BN and LC16m8

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge

Single-chain A35R-M1R-B6R Trivalent Mrna Vaccines Protect Mice Against Both Mpox Virus and Vaccinia Virus

MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to MVA-BN Vaccination